Erisyon
Founded 2018 · 7 employees on LinkedIn · 2 known investors
Erisyon is a biotechnology company that develops technology to advance scientific and health discoveries, building on research from the University of Texas at Austin's Center for Systems and Synthetic Biology. It was founded in 2018 by a group of technologists and entrepreneurs.
Investors · 2
Founder mafia
2 people who came through Erisyon went on to found or lead other companies.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $216.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $247.9K |
| National Science Foundation | Phase ISTTR | 2020 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Erisyon do?
- Erisyon is a biotechnology company that develops technology to advance scientific and health discoveries, building on research from the University of Texas at Austin's Center for Systems and Synthetic Biology. It was founded in 2018 by a group of technologists and entrepreneurs.
- Who are Erisyon's investors?
- Erisyon's investors include Catalio Capital Management, LP, Foothill Ventures.